Literature DB >> 15450416

Missense mutations in cancer suppressor gene TP53 are colocalized with exonic splicing enhancers (ESEs).

Ivan P Gorlov1, Olga Y Gorlova, Marsha L Frazier, Christopher I Amos.   

Abstract

Mutation databases can be viewed as footprints of functional organization of a gene and thus can be used to infer its functional organization. We studied the association of exonic splicing enhancers (ESEs) with missense mutations in the tumor suppressor gene TP53 using the International Agency for Research on Cancer (IARC) mutation database. The goals of the study were: (i) to verify the hypothesis that deleterious missense mutations are colocalized with ESEs; (ii) to identify potentially functional ESE sites in the open reading frame (ORF) of the TP53. If some sequence functions as a splicing enhancer, then nucleotide substitutions in the site will disturb splicing, abrogate p53 function, and cause an increased susceptibility to cancer. Therefore, among cancers showing p53 mutations, more missense mutations are expected within functional ESE sites as compared to non-functional ESE motifs. Using several statistical tests, we found that missense mutations in TP53 are strongly colocalized with ESEs, and that only a small fraction of ESE sites contributes to the association. There are usually one or two ESEs per exon showing a statistically significant association with missense mutations--so-called significant ESE sites. In many respects significant ESE sites are different from those that do not show association with missense mutations. We found that positions of significant ESE sites are codon-dependent--significant ESEs preferentially start from the first position of a codon, whereas non-significant ESEs show no position dependence. Significant ESEs showed a more limited set of sequences compared to non-significant ESEs. These findings suggest that there is a limited number of missense mutations that influence ESE sites and our analysis provides further insight into the types of sites that harbor exonic enhancer elements.

Entities:  

Mesh:

Year:  2004        PMID: 15450416     DOI: 10.1016/j.mrfmmm.2004.04.014

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  7 in total

1.  Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer.

Authors:  Karsten Bork Nielsen; Suzette Sørensen; Luca Cartegni; Thomas Juhl Corydon; Thomas Koed Doktor; Lisbeth Dahl Schroeder; Line Sinnathamby Reinert; Orly Elpeleg; Adrian R Krainer; Niels Gregersen; Jørgen Kjems; Brage Storstein Andresen
Journal:  Am J Hum Genet       Date:  2007-01-18       Impact factor: 11.025

2.  Recognition of functional genetic polymorphism using ESE motif definition: a conservative evolutionary approach to CYP2D6/CYP2C19 gene variants.

Authors:  Mitra Samadi; Laleh Beigi; Fatemeh Yadegari; Alireza Madjid Ansari; Keivan Majidzadeh-A; Maryam Eskordi; Leila Farahmand
Journal:  Genetica       Date:  2022-08-01       Impact factor: 1.633

3.  Effect of BRCA2 sequence variants predicted to disrupt exonic splice enhancers on BRCA2 transcripts.

Authors:  Phillip J Whiley; Christopher A Pettigrew; Brooke L Brewster; Logan C Walker; Amanda B Spurdle; Melissa A Brown
Journal:  BMC Med Genet       Date:  2010-05-28       Impact factor: 2.103

4.  Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics.

Authors:  Sven Arnold; Daniel D Buchanan; Melissa Barker; Lesley Jaskowski; Michael D Walsh; Genevieve Birney; Michael O Woods; John L Hopper; Mark A Jenkins; Melissa A Brown; Sean V Tavtigian; David E Goldgar; Joanne P Young; Amanda B Spurdle
Journal:  Hum Mutat       Date:  2009-05       Impact factor: 4.878

5.  Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1 gene with missense sequence changes and in-frame deletions, but not polymorphisms.

Authors:  Christopher Pettigrew; Nicola Wayte; Paul K Lovelock; Sean V Tavtigian; Georgia Chenevix-Trench; Amanda B Spurdle; Melissa A Brown
Journal:  Breast Cancer Res       Date:  2005-09-22       Impact factor: 6.466

Review 6.  Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment.

Authors:  Roman Hrstka; Philip J Coates; Borivoj Vojtesek
Journal:  J Cell Mol Med       Date:  2009-03       Impact factor: 5.310

7.  Missense mutations of MLH1 and MSH2 genes detected in patients with gastrointestinal cancer are associated with exonic splicing enhancers and silencers.

Authors:  Ming Zhu; Hui-Mei Chen; Ya-Ping Wang
Journal:  Oncol Lett       Date:  2013-03-11       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.